 respons patient advanc ovarian carcinoma gynecolog oncolog group studi second-lin therapi patient patient stage iii IV epitheli ovarian cancer diseas primari surgeri first-lin chemotherapi tamoxifen mg respons eighteen percent patient complet respons CR partial respons PR thirty-eight percent patient short-term diseas stabil CR median durat month last month patient PR stabl diseas median durat respons month maximum durat month estrogen receptor tumor tissu patient CR estrogen receptor level patient stabl progress diseas measur estrogen receptor